The incidence of inflammatory bowel disease (IBD) continues to rise in the world, and now affects more than 1.6 million Americans. We currently have a better understanding of the pathogenesis of IBD, allowing for the development of new therapies targeting the inflammatory pathways. Hence, the management of this complex disease is in turn becoming complex, where the clinician needs to use evidence-based medicine to personalize the use of the appropriate therapy for each individual patient. Becoming familiar with therapeutic drug monitoring and disease monitoring is essential in order to maximize the therapeutic benefit of drugs and the chance of maintaining IBD patients in remission and preventing complications. Patients with long-standing IBD carry an increased risk of colon cancer, and the IBD therapies available have potential side effects. It is essential for healthcare providers to use current guidelines in prevention and screening of these complications in order to improve patient health and quality of care. IBD not only affects the gastrointestinal tract, but also several other systems, often requiring a multidisciplinary approach to the patients involving several medical specialties, colorectal surgery and radiology as well as nutrition support.

Other autoimmune and inflammatory diseases of the GI tract, such as eosinophilic esophagitis, celiac disease, microscopic colitis, auto-immune pancreatitis, appendicitis and diverticulitis, often present a challenge to the healthcare providers as symptoms of diagnosis, management and disease monitoring. New guidelines in the management of these diseases have been recently published, and need to be promptly applied and individualized to patients.

The purpose of this symposium is to provide up-to-date information on the pathogenesis of the disease process, as well as evidence-based recommendations on the management and monitoring of IBD and other autoimmune and inflammatory disorders. Through this course, the gap between state of the art practice and current practices will be closed in order to provide a high quality, comprehensive, multidisciplinary approach to patients with IBD. We believe this approach will improve the quality of care provided to patients, decrease the risk of complications and morbidity, and reduce the overall burden of IBD on the patient and society.

CME ACCREDITATION
MedStar Georgetown University Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
MedStar Georgetown University Hospital designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCE
This conference is intended for gastroenterologists, pathologists, pediatricians, radiologists, surgeons, internists, residents, nurse practitioners, medical students and other healthcare providers interested in the treatment of IBD, inflammatory pathologies of the GI tract and state of the art endoscopic advances.

LEARNING OBJECTIVES
Inflammatory Bowel Disease:
• Implement quality measures in IBD
• Utilize different biologics in treatment of IBD
• Examine the role of therapeutic drug monitoring in IBD and apply it in clinical practice
• Manage IBD in pregnancy
• Apply the new recommendations for the management of colorectal dysplasia in IBD
• Recognize and manage rheumatological complications in IBD
• Implement nutrition therapy and support in IBD
• Diagnose and manage primary sclerosing cholangitis and cholangiocarcinoma
• Apply a multidisciplinary approach when treating IBD and its complications

Other Autoimmune and Inflammatory Diseases in Gastroenterology:
• Evaluate and treat eosinophilic esophagitis
• Diagnose and treat celiac disease and microscopic colitis
• Recognize and manage autoimmune pancreatitis
• Apply the new guidelines for the treatment of diverticulitis and appendicitis

For updated program information and to register online, please visit: http://CME.MedStarHealth.org/IBD

COURSE DIRECTORS:
Aline Charabaty, MD
MedStar Georgetown University Hospital
Washington, DC

Mark C. Mattar, MD
MedStar Georgetown University Hospital
Washington, DC

Inflammatory Bowel Diseases
and Other Inflammatory Pathologies of the GI Tract
APRIL 29, 2017 • THE RITZ-CARLTON • WASHINGTON, DC

Inflammatory Bowel Diseases and
Other Inflammatory Pathologies of the GI Tract
APRIL 29, 2017 • THE RITZ-CARLTON • WASHINGTON, DC
SESSION 2: Multidisciplinary Management of Inflammatory Bowel Disease
Moderator: Mark C. Mattar, MD
10:30 AM
Management of IBD Related and Drug-Induced Rheumatologic Manifestations
Angela B. Worthing, MD
10:35 AM
Management of IBD Related and Drug-Induced Liver Injury
James H. Lewis, MD
10:55 AM
Role of Nutrition and Nutritional Supplements in IBD
Yuliya Rekhtman, MD
11:10 AM
MR Imaging of Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma
R agre P, MD, MPH
11:20 AM
Endoscopic Management of PSC and Cholangiocarcinoma
Rob C. Good, MD
11:35 AM
Surgical Management of Cholangiocarcinoma
Lynt B. Johnson, MD, MBA
11:40 AM
Case Presentation and Panel Discussion
Moderator: Nidhi Malhotra, MD
11:50 AM
Lunch and Visit the Exhibits
12:10 PM
12:15 PM
Lunch Session: What You Need to Know About Digestives in IBD in 2017
Stan T. Hailer, MD
3:05 PM
Break and Visit the Exhibits